Moving precision oncology forward with novel drug targets

Indivumed Therapeutics is a biotech company focused on precision oncology.  With a data driven approach we discover novel drug targets and partner with the pharmaceutical industry to develop precision cancer therapeutics.  

With our global network of selected partner clinics, we utilize proprietary protocols and procedures to collect tissue of unmatched quality and variety. By systematically characterizing the tissue at a molecular level and linking it with longitudinal clinical data, we discover novel targets that would otherwise be undetectable.

Combining biomathematics, bioinformatics and cell biology, we select targets and design proof-of-concept drug screening assays that create a higher chance of success further down the pharmaceutical drug discovery pipeline.  

We envision a world where precision therapy offers a cure for every cancer patient.

Highest quality biospecimens make all the difference

The basis of our activity is a strict clinical standard, to which we have been adhering to for the past 20 years. Biospecimen and associated data quality is crucial to making relevant details of a cancer disease transparent.

To ensure this quality, our global clinical partners apply numerous proprietary standard operating procedures (SOPs) to the collection and processing of biospecimens, achieving an ischemia time for tissue of under ten minutes. Also, the collection of extensive longitudinal clinical patient data, covering around 300 individual data points, is performed following defined standards.

We have developed and refined these procedures through years of experience working alongside surgeons and pathologists in our network.

Target Discovery - using multivariate, multi-omics analyses

The high quality of our biospecimens allows us to use a full multi-omics approach. Using next generation sequencing and mass spectrometry technologies, we extract in-depth molecular information (genomics, transcriptomics, miRNA, proteomics, and phospho-proteomics data from both normal and tumor tissue) to feed our comprehensive cancer database.  

Our data-driven target identification process combines biomathematics and bioinformatics in a multi-omics, multivariate approach to uncover hidden patterns in the vast amount of data and leads to the discovery of novel therapeutic targets.

Target Validation - end-to-end comparability with patient-based cellular models

Target validation is performed in 2D and 3D cellular models derived from patient material from the same cohorts analysed for target discovery. These models provide a better representation of the tumor’s physiological processes and display characteristic features of the disease. This approach ensures end-to-end comparability and increases the likelihood of successful therapeutic development further down the pipeline.

Target Refinement - preparing the package for R&D partnerships

Our IP-protected packages include screening-ready targets. The protein class and biochemical characteristics, cellular location, and biological function are further defined. Proof-of-concept drug screening assays are established for cell-free and cell-based compound screening. Set up for reproducibility within the R&D-pipelines of our pharmaceutical partners, our unique target packages can result in new drugs with a higher chance of reaching the market.